1
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael J Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck Sharp & Dohme, Matthew A Leff, David A Mutard, August 30, 2011: US08008317 (4 worldwide citation)


The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)


The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


3
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas DP Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt Activity. Merck And Co, November 20, 2008: US20080287457-A1


The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


4
Kevin Rodzinak
Donna J Armstrong, Essa H Hu, Michael J Kelly III, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Michael A Rossi, Philip E Sanderson, Jiabing Wang: Inhibitors of akt activtiy. Merck, September 2, 2010: US20100222321-A1


The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


5
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Banka, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do: Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors. Array BioPharma, Covenentech, Viksnins Harris & Padys PLLP, November 22, 2011: US08063050 (25 worldwide citation)


The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatmen ...


6
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Banka, Jun Liang, Brian Safina, Jun Li, Christine Chabot: Pyrimidyl cyclopentanes as AKT protein kinase inhibitors. Array BioPharma, Genertech, Viksnins Harris & Padys PLLP, August 23, 2011: US08003651 (22 worldwide citation)


The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for ...


7
Jun Liang, Shijun Shen, Meng Li, Juan Zhang, Rui Hu, Jun Gong: Method and apparatus for longest prefix matching based on a trie. Huawei Technologies, Morris Manning Martin, Tim Tingkang Xia Esq, May 26, 2009: US07539153 (14 worldwide citation)


The present invention discloses a method and apparatus for longest prefix matching. The method includes (A) reading a current-level trie node (TNODE) in the trie, (B) determining whether an offset field of the TNODE indicates that a matched prefix exists in an upper level node and, if so, adding the ...


8
John W Erickson, Dominique P Bridon, Martin Robitaille, Grant A Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra DeMeyer: Long lasting fusion peptide inhibitors for HIV infection. Conjuchem Biotechnologies, Lando & Anastasi, June 22, 2010: US07741453 (9 worldwide citation)


The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), ...


9
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Banka, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do: Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors. Array Biopharma, Genentech, Viksnins Harris & Padys PLLP, October 7, 2014: US08853199 (7 worldwide citation)


The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatmen ...


10
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Banka, Jun Liang, Brian Safina, Jun Li, Christine Chabot: Pyrimidyl cyclopentanes as AKT protein kinase inhibitors. Array BioPharma, Genentech, Viksnins Harris & Padys PLLP, September 30, 2014: US08846681 (7 worldwide citation)


The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for ...



Click the thumbnails below to visualize the patent trend.